<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28517">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02040116</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00022197</org_study_id>
    <nct_id>NCT02040116</nct_id>
  </id_info>
  <brief_title>Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases</brief_title>
  <official_title>Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest Baptist Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest Baptist Health</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the impact of rapid infusion rituximab on the
      incidence of infusion-related reactions in patients with Autoimmune Diseases.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of infusion related reactions with rapid infusion compared to standard infusion</measure>
    <time_frame>up to 24 hours after infusion on Day 14</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients are given therapy on day 1 and if infusion is tolerated with &lt; grade 2 reaction based on the CTCAE v4 then then will proceed to rapid infusion on day 14 which is given over 2 hours. The number and grade of infusion reaction is measured for all 20 patients and in all infusions given.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in chair time with rapid infusion compared to standard infusion</measure>
    <time_frame>up to 24 hours after infusion on day 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>rituximab infusion</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Every patient is getting the same therapy of rituximab.  If day 1 is tolerated at standard infusion then day 14 and beyond will be given as rapid infusion over 20 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapid Infusion Rituximab</intervention_name>
    <description>Participants will receive their first infusion of rituximab at the standard infusion rate provided in the manufacturer labeling. If they tolerate this infusion with a grade 2 of less infusion-related reaction, the next infusion will be administered as a 90 minute rapid infusion.</description>
    <arm_group_label>rituximab infusion</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Autoimmune patient at Wake Forest Baptist Health that is eligible for rituximab
             therapy

          -  Tolerate the standard infusion rituximab with ≤ grade 2 hypersensitivity reaction

          -  Consent to participate in the rapid infusion study

          -  Age ≥ 18 years ≤ 80 years

        Exclusion Criteria:

          -  Tolerate the standard infusion rituximab with ≥ grade 3 hypersensitivity reaction

          -  Neurocognitive impairment (i.e. dementia,  Alzheimers, et al)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LeAnne D Kennedy, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest Baptist Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Pharr, MD</last_name>
    <phone>3367163869</phone>
    <email>epharr@wakehealth.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 17, 2014</lastchanged_date>
  <firstreceived_date>January 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wake Forest Baptist Health</investigator_affiliation>
    <investigator_full_name>LeAnne Kennedy, PharmD, BCOP, CPP</investigator_full_name>
    <investigator_title>Pharmacy Clinical Specialist</investigator_title>
  </responsible_party>
  <keyword>Rapid Infusion Rituximab</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
